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Sex can be an important determinant of cancer phenotype, and
exploring sex-biased tumor biology holds promise for identifying
novel therapeutic targets and new approaches to cancer treatment.
In an established isogenic murine model of glioblastoma (GBM), we
discovered correlated transcriptome-wide sex differences in gene expression, H3K27ac marks, large Brd4-bound enhancer usage, and Brd4
localization to Myc and p53 genomic binding sites. These sex-biased
gene expression patterns were also evident in human glioblastoma
stem cells (GSCs). These observations led us to hypothesize that
Brd4-bound enhancers might underlie sex differences in stem cell
function and tumorigenicity in GBM. We found that male and female GBM cells exhibited sex-specific responses to pharmacological
or genetic inhibition of Brd4. Brd4 knockdown or pharmacologic
inhibition decreased male GBM cell clonogenicity and in vivo tumorigenesis while increasing both in female GBM cells. These results
were validated in male and female patient-derived GBM cell lines.
Furthermore, analysis of the Cancer Therapeutic Response Portal of
human GBM samples segregated by sex revealed that male GBM
cells are significantly more sensitive to BET (bromodomain and
extraterminal) inhibitors than are female cells. Thus, Brd4 activity
is revealed to drive sex differences in stem cell and tumorigenic
phenotypes, which can be abrogated by sex-specific responses to
BET inhibition. This has important implications for the clinical evaluation and use of BET inhibitors.
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cancer risk and progression, with the ultimate goal of incorporating
sex-informed approaches to treatment to improve survival of all
patients.
While disease-related sex differences are often mediated through
acute sex hormone actions, sex differences in the rates of multiple
brain tumors are evident at all ages as well as in neutered and
nonneutered dogs (8), suggesting that factors other than circulating
sex hormones underlie this skewing (13). Such factors may include
the organizational or epigenetic effects of transient in utero sex
hormones, the effects of X chromosome alleles that escape inactivation, or the extragonadal expression of nonpseudoautosomal
Y chromosome–encoded genes (14–17).
We previously discovered that a genetically engineered model
of GBM, involving combined loss of neurofibromin (NF1) and
p53 function in murine neocortical postnatal day 1 (p1) astrocytes
(male and female GBM astrocytes), exhibits sex differences in vivo
(18, 19), including proliferation, clonogenic stem-like frequency
Significance
Consistent sex differences in incidence and outcome have been
reported in numerous cancers including brain tumors. GBM, the
most common and aggressive primary brain tumor, occurs with
higher incidence and shorter survival in males compared to females. Brd4 is essential for regulating transcriptome-wide gene
expression and specifying cell identity, including that of GBM. We
report that sex-biased Brd4 activity drives sex differences in GBM
and renders male and female tumor cells differentially sensitive
to BET inhibitors. The observed sex differences in BETi treatment
strongly indicate that sex differences in disease biology translate
into sex differences in therapeutic responses. This has critical
implications for clinical use of BET inhibitors further affirming the
importance of inclusion of sex as a biological variable.
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ntil recently, most basic and clinical research focused on
investigating factors that influence disease susceptibility and
progression without regard to biologic sex. However, mounting
evidence has revealed sex differences in the incidence, age of onset,
and outcome of numerous human diseases, including cardiovascular
diseases, metabolic diseases, asthma, autoimmune diseases, birth
defects, neurological diseases, psychiatric disorders, and cancers
(1–4). The preponderance of sex differences in disease incidence
and outcome led to the implementation of new guidelines by the
NIH regarding inclusion of sex as a biological variable in all research.
Glioblastoma (GBM), the most common, aggressive, and incurable form of primary brain cancer (5, 6), is more prevalent in
males, regardless of race or region of the world (male to female
incidence of 1.6:1) (7–10). This sex difference extends across
species; a male prevalence also occurs in spontaneous GBM in
large dogs, suggesting a fundamental effect of sex on GBM risk
(11). In addition to the sex difference in GBM incidence, Ostrom
et al. documented a survival advantage for female GBM patients
(12). The reasons for these sex differences in GBM incidence and
outcome are largely unknown. We hypothesized that studying sex
differences in GBM biology will inform the mechanisms underlying
PNAS 2021 Vol. 118 No. 16 e2017148118
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and in vivo tumorigenesis, cell cycle regulation (18, 19), gene expression (18), and chemotherapy response (18), that mimic those
observed in GBM patients (18, 19). Sex differences in the tumorigenic phenotype were validated in a second CRISPR-in utero
electroporation murine model of GBM. In this model, guide sequence inserts targeting Nf1 and p53 were injected into the lateral
ventricles of embryonic pups of male and female mice, and progenitor cells were targeted via bioelectroporation. Both male and
female mice developed tumors; however, male mice exhibited an
accelerated tumorigenic phenotype with a shorter median survival
(18). Accordingly, data generated from both our in vitro and
in vivo murine GBM models with combined loss of neurofibromin
and p53 function further affirm that sex differences in tumorigenesis are evident in different mouse strains and independent of
the method by which p53 function is abrogated. Together, these
human and mouse data suggest that male and female GBM cells
are differentially vulnerable to oncogenic events and to the cytotoxic effects of chemotherapy.
What are the factors that control these differences between male
and female cells? In a recent multi-institutional study, we found that
longer survival for male and female GBM patients after standard
surgery, radiation, and chemotherapy is dependent upon different
transcriptional programs (20). We discerned multiple sex-specific
transcriptional subtypes of GBM that correlated with survival in a
sex-specific manner. We hypothesized that these sex-specific transcriptional states arise through sex-specific epigenetics, analogous to
mechanisms that drive normal sexual differentiation (21, 22).
Bromodomain and extraterminal (BET) family proteins are
epigenetic readers of histone lysine acetylation and function as
coactivators or corepressors of gene expression by recruiting
specific transcriptional complexes to target genes (23). The BET
family member Brd4 is essential for regulating transcriptomewide gene expression and specifying cell identity, including that
of GBM (24–26). Additionally, Brd4 is an emerging drug target
for epigenetic interventions (23–34). Here, we show that sex differences in tumor phenotype are dependent on differential Brd4bound enhancer regulation of stem cell–like phenotypes in male
and female murine and human GBM cells. In vitro and in vivo
studies of genetic or pharmacological Brd4 inhibition, as well as
data mining of the Cancer Therapeutics Response Portal (CTRP),
indicate that male and female murine and human GBM cells are
differentially sensitive to inhibition of Brd4, resulting in decreased
in vitro clonogenicity and in vivo growth of male tumors and opposite effects on female cells and tumors. Understanding the extent to which sex differences in GBM are mediated by epigenetic
mechanisms will be imperative to understanding the biology of sex
differences in GBM, stratifying patients for treatment with epigenetic agents, and anticipating potential sex-biased toxicities
following systemic disruption of epigenetics.
Results
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Male and Female GBM Cells Utilize Different Sets of Brd4-Bound
Enhancers. Previously, we reported correlations between sex dif-

ferences in tumorigenicity and gene expression in our murine
model of GBM (male and female GBM astrocytes lacking function of both NF1 and p53, see SI Appendix, Supplementary Materials and Methods for full details) (18, 19). Of the sex-biased
differences in gene expression observed in this model, 50% were
concordantly sex-biased in human GBM expression data (18). This
concordance demonstrated that our murine model recapitulates
important transcriptional pathways that govern clinically relevant
sex differences in human GBM. In addition, we found correlations
between sex differences in survival and gene expression in patients
with GBM (20). We therefore determined whether these distinct
GBM transcriptional states were the result of sex-specific enhancer activity and whether such states could be perturbed with
small molecules that target epigenetic regulators that bind at these
2 of 12 | PNAS
https://doi.org/10.1073/pnas.2017148118

enhancers. We prioritized Brd4-bound enhancers for analysis because these enhancers play key roles in establishing cell identity
(25, 30–34) and may regulate the cell-intrinsic sex differences observed
in GBM. Brd4 is an epigenetic reader that binds acetylated histones
H3 and H4 throughout the entire cell cycle and is deregulated in
numerous cancers (35). Brd4 promotes epithelial-to-mesenchymal
transition, stem cell–like conversion, and pluripotency (26, 28, 36).
Brd4 pharmacological inhibition has shown therapeutic activity in
a number of different cancer models (37–41).
To evaluate a potential role for Brd4 in mediating sex differences
in GBM, we mapped Brd4 genomic localization in male and female
GBM astrocytes (highly active Brd4-bound enhancers and typical
Brd4-bound enhancers) using transposon calling cards (42, 43) to
identify enhancers differentially bound by Brd4. To do so, we fused
the piggyBac (PB) transposase to the C terminus of the Brd4 protein, endowing the transposase with the ability to direct the insertion
of the PB transposon into the genome close to Brd4-binding sites.
Five biological replicates were carried out, and the correlation between replicates was r > 0.9 for all pairwise comparisons (SI Appendix, Fig. S1A). Using this protocol, we mapped ∼1.25 million
unique insertions directed by the Brd4-PBase fusion for each male
and female sample. As Brd4 is an epigenetic reader of the acetylated lysine 27 residue of histone H3 (H3K27ac), we confirmed that
these newly identified Brd4-bound enhancers were enriched for
H3K27ac. We performed H3K27ac chromatin immunoprecipitation sequencing (ChIP-seq) in male and female GBM cells to
identify the genomic regions enriched for this well-known marker of
active enhancers (44). Three biological replicates were analyzed,
and the correlation between replicates was r > 0.9 for all pairwise
comparisons (SI Appendix, Fig. S1B). As expected, data collected
from calling cards and H3K27ac ChIP-seq revealed a high concordance between Brd4-bound enhancers and H3K27ac enrichment. A representative example of concordant Brd4 binding and
H3K27ac in male and female GBM astrocytes at high- and lowenriched regions is depicted in Fig. 1A. We next analyzed the distances from Brd4-binding sites to the nearest H3K27ac-enriched
regions. Brd4-binding sites were significantly enriched at H3K27ac
candidate enhancer regions (Fig. 1B) and display concordant gene
expression levels (Fig. 1C) indicative of active Brd4-bound enhancers (P < 0.01). More specifically, 82 and 81% of Brd4-bound
enhancers were localized within 200 base pairs (bp) of H3K27ac
peaks in male and female GBM cells, respectively.
Having established that our genomic data were reproducible
and that Brd4-binding sites occur at genomic regions enriched
for H3K27ac, we next sought to identify the genomic loci that
were differentially bound by Brd4 in male and female cells. We
identified 2,679 enhancers (20% of all Brd4-bound enhancers in
male GBM cells) that bound more Brd4 protein in males and
2,778 enhancers (21.2% of all Brd4-bound enhancers in female
GBM cells) that bound more Brd4 protein in females (Fig. 2A).
The Brd4 signal intensity for these male-biased and female-biased
enhancers in male and female GBM astrocytes is depicted in
Fig. 2B. To validate these putative male- and female-biased enhancers using an orthogonal method, we analyzed their H3K27ac
status and found that the loci that bound Brd4 in a sex-biased
manner displayed sex-biased enrichment of H3K27ac (Fig. 2C).
Chromosome location analysis for these sex-biased Brd4-bound
enhancers revealed that only 0.13 and 3.11% of male-biased
Brd4-bound enhancers were located on the Y and X chromosomes, respectively, and that only 4.29% of female-biased Brd4bound enhancers were located on the X chromosome, indicating
that the observed differences in Brd4-bound enhancers are not
simply due to differential Brd4 enhancer enrichment on sex
chromosomes. The majority of enhancers exhibited a sex bias in
Brd4 occupancy, while a subset appeared to be sex specific.
We will collectively refer to these enhancers as sex biased.
Kfoury et al.
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Representative examples of sex-specific, Nkx2.1, and sexbiased, Zic1/4, enhancers are depicted in Fig. 2 D and E.
Nkx2.1 functions both as a “lineage survival” oncogene and
tumor suppressor in lung adenocarcinomas (45, 46), whereas
Zic1 acts as a tumor suppressor in breast and thyroid cancers (47,
48), supporting the potential context-dependent dual role of Brd4 in
oncogenesis. This is the first demonstration of differential Brd4bound enhancer usage by male and female cells of any kind, suggesting that these enhancers may function in sexual differentiation
in a manner similar to their role in determining cell identity and fate
(25, 30–32, 49). A violin plot illustrating the full distribution of the
enrichment signal for male- and female-biased loci and shared
peaks is depicted in Fig. 2F.
We next sought to identify the genes regulated by these sexbiased Brd4-bound enhancers. It is challenging to reliably link
enhancers to the genes they regulate (50), so we used conservative
criteria: we linked enhancers to the nearest gene within a 5 kb
genomic distance. This analysis revealed 1,740 male-biased genes
and 1,604 female-biased genes. Pathway enrichment analysis using
the Genomatix Pathway System (GePS) of male-biased enhancergene pairs revealed functional enrichment for glioblastoma, cell
proliferation, cell cycle, regulation of transcription, tumor angiogenesis, and cancer stem cells. Similar analysis on female-biased
enhancer-gene pairs showed an enrichment in pathways involved
in cell differentiation, glioblastoma, regulation of transcription,
cell migration, and neural stem cells (SI Appendix, Table S1).
Based on our observation of sex-biased Brd4-bound enhancer
usage between male and female GBM cells, we profiled male and
female GBM cells with RNA sequencing (RNA-seq). For each
condition, three biological replicates were performed; the data
were highly reproducible (Pearson r ≥ 0.96 for all pairwise comparisons) (SI Appendix, Fig. S1C) and indicated differential expression of 3,490 transcripts (false discovery rate [FDR] < 0.05).
We next integrated the male- and female-biased Brd4-regulated
genes with the differentially expressed genes between male and
female GBM astrocytes and narrowed the list of differentially
Kfoury et al.
Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma

regulated sex-biased Brd4-bound genes to 1,296, of which 52.4%
were male-biased and 47.6% were female-biased Brd4-regulated
genes. A heatmap depiction of the top 400 differentially regulated
sex-biased Brd4-bound genes is presented in Fig. 2G. Pathway
enrichment analysis for the 1,296 differentially regulated sexbiased Brd4-bound genes was performed using a combination
of the Kyoto Encyclopedia of Genes and Genomes pathway
and GePS. Classification of these genes according to function
revealed a significant number of relevant and important pathways, including cell differentiation, glioblastoma, cell proliferation, cell migration and invasion, tumor angiogenesis, stem
cell functions, and DNA-binding transcription factors (Fig. 2H and
SI Appendix, Table S2). Thus, these sex-specific transcriptomic
differences in core cancer pathways likely arise from male- and
female-biased Brd4-bound enhancer activity.
We next sought to determine whether these sex-specific transcriptome differences are also present in human GBM samples.
To do so, we reanalyzed published RNA-seq data of 43 human
glioblastoma stem cells (GSCs) and segregated them by sex (51,
52). We found 246 differentially regulated genes between male
and female GSCs, of which 223 were up-regulated in males and 23
were up-regulated in females (log2FC 1.5 and FDR 0.05). We
then compared the gene lists of sex-biased differentially regulated
genes in human GSCs with those of the murine GBM astrocytes at
the same cutoff parameters (log2FC 1.5 and FDR 0.05; 981 and
771 up-regulated genes in male and female GBM cells, respectively) and found an overlap in gene identity and direction of
change for both males (17.5% of human male-biased differentially
expressed genes, P value 0.001) and females (17.4% of human
female-biased differentially expressed genes, P value 0.04) (SI
Appendix, Table S3). P values were calculated using the cumulative hypergeometric distribution. A volcano plot depicting all
mouse sex-biased significantly expressed genes with color-coded
concordant human sex-biased genes (blue circles show malebiased genes and red circles show female-biased genes; log2FC
1.5 and FDR 0.05) is presented in Fig. 2I. The expression patterns
PNAS | 3 of 12
https://doi.org/10.1073/pnas.2017148118
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Fig. 1. Concordance between Brd4-bound enhancers, H3K27ac enrichment, and gene expression in mouse GBM astrocytes. (A) A representative example of
concordant Brd4 and H3K27ac binding at high- and low-enriched regions in male and female GBM astrocytes. (B and C) Heatmaps and intensity plots of
H3K27ac signal at sex-biased Brd4-enriched peaks (+/−10 kb from the Brd4 peak center) in male (B) and female (C) GBM cells. For each sex-biased Brd4enriched peak, the expression values of the nearest gene are presented in a dot plot in which the yellow dotted line depicts the average gene expression
levels of 50 genes (Density refers to the fraction of genes). These analyses revealed that Brd4-binding sites are significantly enriched at H3K27ac candidate
enhancer regions and display concordant gene expression levels indicative of active Brd4-bound enhancers (P < 0.01).
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Fig. 2. Male and female GBM cells have sex-biased Brd4-bound enhancers. (A) Venn diagram showing the number of unique male (2,679), unique female (2,778),
and overlapping (10,312) Brd4-enriched peaks identified in GBM astrocytes. (B) A heatmap depiction of the number of Brd4 insertions at male- and female-biased
Brd4-enriched peaks in GBM astrocytes (normalized data). (C) A heatmap analysis of H3K27ac signal intensity (read depth) at male and female-biased Brd4-enriched
peaks in GBM astrocytes. (D) Nkx2.1 and (E) Zic1/4 illustrate male-specific and female-biased genes, respectively, associated with differential Brd4-binding affinity and
H3K27ac enrichment. The x-axis (blue arrows) of all tracks corresponds to genomic location of the gene. The y-axis of calling card tracks represents the log10 scale of
sequencing reads for each insertion as indicated by circles. The y-axis of ChIP-seq tracks represents the number of uniquely mapped reads. (F) Violin plot illustrating the
full distribution range of the enrichment signal for male- and female-biased loci and shared peaks at different genomic locations. (G) RNA abundance (RNA sequencing) in male and female GBM cells for differentially regulated sex-biased Brd4-bound genes (n = 3). (H) Pathway enrichment analysis for differentially regulated
sex-biased Brd4-bound genes in male and female GBM astrocytes. (I) Concordance in sex-specific gene expression patterns between murine GBM lines and human
GSCs. Volcano plot depicting all mouse sex-biased significantly expressed genes with color-coded concordant human sex-biased genes (blue circles, male-biased genes;
red circles, female-biased genes; log2FC 1.5 and FDR 0.05) genes. The x-axis represents mouse log2 fold change of male/female ratio for each significantly expressed
sex-biased gene with its corresponding (−) log10 FDR value on the y-axis. (J) Gene expression pattern, whole-exome sequencing, and clinical phenotype data from the
TCGA GBM datasets for two representative examples of concordant human and mouse male (blue) and female (red) sex-biased genes.
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Pathway description
Male GBM Cells: 20 genes/motifs
Transcription factor activity, sequence-specific DNA
binding
Neoplastic cell transformation
Cell proliferation
Pluripotent stem cells
Angiogenesis
Mitogen-activated protein kinase signaling
Stem cell differentiation
Female GBM Cells: 26 genes/motifs
Transcription factor activity, sequence-specific DNA
binding

Genes
Myc, Hoxb4, Max, Pou5f1, Fli1, Klf1, Bach1, Fosl2, Bach2,
Nfe2l2, Mafk, Isl1, Nfe2, Jun, Klf5, Fosl1, Batf, Lhx3, Atf3
Myc, Hoxb4, Max, Pou5f1, Fli1, Klf1, Bach1, Fosl2, Bach2,
Nfe2l2, Mafk, Nfe2, Jun, Klf5, Klf14, Fosl1, Batf, Lhx3, Atf3
Myc, Hoxb4, Fosl2, Isl1, Nfe2, Jun, Fosl1, Atf3
Myc, Hoxb4, Max, Pou5f1, Klf1, Mafk, Isl1, Klf5, Egr1, Max,
Fosl2, Jun,
Nfe2l2, Isl1, Jun, Klf5
Max, Fosl2, Jun, Fosl1, Atf3
Pou5f1, Nfe2l2, Isl1, Batf, Hoxb4

Mybl1, Rela, Gata4, Ets1, Atf4, Arnt, Maff, Irf1, Smad2, Irf2,
Prdm1, Irf3, Ddit3, Ebf1, Smad4, Myod1, Ep300, Irf4, Cebpa,
Pgr, Ctcf, Trp53
Growth arrest
Mybl1, Hoxb13, Atf4, Irf1, Smad2, Ddit3, Ebf1, Myod1, Cebpa,
Trp53
Negative regulation of cell cycle
Mybl1, Ets1, Irf1, Ddit3, Ep300, Cebpa, Trp53
Histone modification and chromosome organization Mybl1, Hoxb13, Atf4, Irf1, Smad2, Ddit3, Ebf1, Myod1, Cebpa,
Trp53
Cyclin-dependent kinase inhibitor 1 signaling
Hoxb13, Irf1, Myod1, Trp53
Estrogen receptor signaling
Hoxb13, Arnt, Irf4, Pgr

Adjusted
P value

# of
genes

<0.0001

19

<0.0001

19

<0.0001
<0.0001

8
8

<0.0001
1.10E-02
<0.0001

4
5
5

<0.0001

22

<0.0001

10

1.00E-03
1.00E-03

7
6

1.00E-03
3.00E-03

4
4

*Subset of enriched pathways for enriched motifs in male and female GBM cells.

of two representative examples of concordant male-biased (RET)
and female-biased genes (SERPINF1) are illustrated in Fig. 2J,
with gene expression (RNA-seq), whole-exome, and clinical phenotype data collected from TCGA GBM data (53). This concordance of sex-biased gene expression patterns between our murine
mouse model and the human GSCs validates the sex-specific tumorigenic phenotype observed in our mouse model. Pathway
enrichment analysis for the human and mouse concordant genes
identified functional enrichment for the MAPK family signaling
cascade, cell adhesion, mesenchymal and pluripotent stem cells,
neurofibromatosis, neuroendocrine tumors, and neuron differentiation. Altogether, the mouse and human data suggest the presence of sex-specific transcriptional programs in tumorigenesis that
are regulated by Brd4-bound enhancers in a sex-biased manner.
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Depletion or Inhibition of the BET Family Protein Brd4 has Differing
Effects on Clonogenicity in Mouse and Human Male and Female GBM
Cells. Our genomic analyses of mouse and human GBM cells sug-

gested to us that Brd4-bound enhancers might regulate a large
number of genes and transcriptional networks in a sex-biased fashion. To test this hypothesis, we performed genetic depletion of individual BET family members in our murine model of GBM. Under
basal conditions, male and female GBM cells expressed Brd3 and
Brd4 messenger RNA (mRNA) at similar levels, whereas Brd2 was
expressed at higher levels in female cells (*P = 0.02) (Fig. 3A). We
evaluated the potency of five short hairpin RNAs (shRNAs) specific
to each of the Brd2, Brd3, or Brd4 genes and selected the shRNAs
that achieved the most robust knockdown of each gene for downstream functional experiments of the tumorigenic phenotype. Brd2,
Brd3, and Brd4 mRNA levels were partially depleted in male and
female GBM cells after infection with the corresponding lentiviral
shRNAs (Fig. 3B). Knockdown of Brd2 did not affect clonogenic
frequency in either male or female cells as measured by the extreme
limiting dilution assay (ELDA) (Fig. 3C). Male GBM cells with
Brd4 knockdown exhibited a decrease in clonogenic frequency,
whereas female cells displayed an increase in clonogenic frequency.
A similar effect on clonogenic frequency was observed following
Kfoury et al.
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Brd3 knockdown in male cells, although it was not as robust as the
effect of Brd4 knockdown. Strong Brd4 effects were observed despite the more modest knockdown of Brd4 compared to Brd3.
Small molecule inhibitors of the BET family of proteins
(BETi) are a novel class of epigenetic compounds that selectively
target BET proteins and have been shown to have promise as
cancer therapeutics, decreasing cell proliferation and invasion in
many cancer types, including GBM (24, 27, 29). However, almost
all of the American Type Culture Collection human cell lines
used in the preclinical studies are of male origin and are therefore potentially uninformative with regard to sex differences in
drug effects. Therefore, we evaluated whether there was a sex
difference in the treatment response to some of the BET inhibitors currently in clinical trials for cancer in our mouse GBM
cells. We treated male and female GBM astrocytes with a panel
of BETi (Fig. 3D), which are being tested in clinical trials (24
clinical trials listed in https://www.clinicaltrials.gov/ and https://
wwwselleckchem.com), and then performed ELDAs to measure
clonogenic cell frequency (54–56). Treatment with BETi reproducibly decreased clonogenic frequency in male GBM cells while
increasing clonogenic frequency in female cells (Fig. 3 E–G and
SI Appendix, Fig. S2). This striking abrogation of sex differences,
driven by sex-specific response to Brd4 inhibition, is illustrated in
response to the Brd4 antagonist JQ1 (Fig. 3F). JQ1 is a
thieno-triazolo-1,4-diazepine that displaces Brd4 from chromatin
by competitively binding to the acetyl-lysine recognition pocket
(37, 38). Treatment of acute myeloid leukemia cells with JQ1
causes a rapid release of Mediator 1 (MED1) from a subset of
enhancer regions that were co-occupied by Brd4, leading to a
decrease in the expression of neighboring genes (57). We treated
male and female GBM cells with either 0.05% dimethyl sulfoxide
(DMSO) or 500 nM JQ1 and then performed ELDAs to measure clonogenic cell frequency. Male cells exhibited greater
clonogenic cell activity than female cells under control conditions. Treatment with JQ1 reproducibly abrogated the basal
differences in clonogenic frequency between male and female
GBM cells by decreasing the clonogenic cell fraction in male
PNAS | 5 of 12
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Table 1. Pathway analysis for enriched motifs in male and female GBM cells*
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Fig. 3. Brd4 inhibition has differing effects on clonogenicity in mouse and human male and female GBM cells. (A) Normalized Brd2, Brd3, and Brd4 mRNA
expression in male and female GBM cells under basal conditions. Brd3 and Brd4 are expressed at equivalent levels between male and female GBM cells, while
Brd2 is expressed at higher levels in female cells. (B) Brd2, Brd3, and Brd4 mRNA expression following lentiviral shRNA infection. mRNA levels in knockdown
samples were normalized to their respective control. (C) Normalized clonogenic cell frequency as determined by ELDA assay in control and Brd2, Brd3, and
Brd4 knockdown male and female GBM cell lines. Knockdown of Brd4 and Brd3 suppresses clonogenic frequency in male GBM cells, while female cells showed
a significant increase in clonogenic frequency following Brd4 knockdown only. Brd2 depletion was without effect. All treatment groups were normalized to
control clonogenic frequency levels. (D) Tabular representation of the BET inhibitors currently in clinical trials and their selectivity to the three BET family
members. (E) Normalized clonogenic cell frequency as determined by ELDA assay in male and female GBM cells treated with DMSO (control) or the indicated
BET inhibitor. BET inhibitors significantly reduced clonogenic cell frequency in male cells and significantly increased clonogenic cell frequency in female cells.
Shaded bars are used to indicate the effect of RVX208, a Brd2/3 inhibitor, as a control for Brd4 inhibition. (F) Frequency of clonogenic stem-like cells as
determined by ELDA assay in male and female GBM cells treated with DMSO or JQ1 (Brd2/3/4 inhibitor). Male cells exhibited greater clonogenic cell activity
than female cells under control conditions. JQ1 significantly reduced clonogenic cell frequency in male cells to levels almost equivalent to female cells under
control conditions, while female cells exhibited an increase in their clonogenic cell frequency. (G) Frequency of clonogenic stem-like cells was measured by
ELDA in male and female GBM astrocytes following RVX-208 treatment, a BD2 inhibitor with selectivity to Brd2 and Brd3. No significant change in clonogenic
frequency was observed in male and female GBM astrocytes following RVX208 treatment. (H) Proliferation assays were performed in mouse GBM cells treated
with DMSO or JQ1. Male cells exhibited greater proliferation than female cells under control conditions. JQ1 significantly reduced growth in male cells to
female basal growth level. (I) Proliferation rates of male and female GBM astrocytes were unaffected by RVX-208 treatment. (J) Normalized clonogenic cell
frequency as determined by ELDA assay in male and female human primary GBM cells treated with DMSO (control), JQ1, or CPI0610. JQ1 treatment significantly reduced clonogenic cell frequency in human primary GBM male cells and slightly increased clonogenic cell frequency in human primary GBM female
cells. CPI0610 treatment had a similar response pattern as JQ1 in male and female human GBM primary cells. (K) Tabular representation of the sex-biased
growth response of human GBM cells to BETi treatment. Male GBM cells are more sensitive to BETi treatment than female GBM cells (CTRP). (*P < 0.05, **P <
0.01, ***P < 0.001, ****P < 0.0001 as determined by two-tailed t test or one-way ANOVA).
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1 μM CPI0610 and then performed ELDA to measure clonogenic cell frequency. Similar to the murine data, treatment with
BETi decreased clonogenic cell frequency in male patientderived GBM cells, while slightly increasing the clonogenic cell
frequency in female patient-derived GBM (Fig. 3J and SI Appendix, Fig. S3). Although we observed the expected trend in
response to BETi treatment in human male and female primary
cell lines, our sample size was small with limited power. Additionally, human GBM samples are intrinsically heterogeneous
with different genetic backgrounds, and hence the magnitude of
treatment effects can be more variable compared to isogenic cell
lines. To expand our sample size, we analyzed the CTRP to examine if human male GBM cells are indeed more sensitive to
BETi than female cells (59). First, we segregated the CTRP
human GBM samples by sex. We then analyzed the cell growth
response of male and female GBM cells to BETi treatment. This
analysis revealed that male GBM cells are more sensitive to
BETi, displaying slower growth and more cell death, consistent
with what we observed using our murine GBM model (Fig. 3K).
While the female stem cell response to BETi treatment data
were variable, a clear difference in response to BET inhibition was
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cells and increasing the clonogenic cell fraction in female cells,
rendering the male JQ1–treated cells equivalent to the female
control cells (Fig. 3F). To confirm that these effects were mediated
by Brd4-bound enhancers, we performed similar experiments using
RVX-208, a BD2 inhibitor with high selectivity to Brd2/3 (58).
Consistent with the Brd2 and Brd3 knockdown results, treatment
with 5 μM RVX-208 for 24 h did not have an effect on the clonogenic frequency of male and female cells (Fig. 3 E and G). Next,
we examined the effect of drug treatment on cell growth and
proliferation. Male cells exhibited decreased proliferation and a
growth phenotype equivalent to control female cells following JQ1
treatment (Fig. 3H), whereas treatment with RVX208 did not
alter proliferation of male and female cells (Fig. 3I). Taken together, these results demonstrate that the sex differences in the
tumorigenic phenotype we observe in our murine GBM cells are
mediated by differential Brd4-bound enhancers and that the response to BET inhibition is sex dependent.
Next, we investigated whether the sex-specific responses to
BETi observed in our murine GBM model were also present in
human GBM. To do so, we treated male and female human
GBM primary cell lines with 0.05% DMSO, 500 nM JQ1, or

Fig. 4. Male and female GBM cells have sex-biased Brd4-bound enhancers and concordant gene expression. Brd4 insertions, H3K27ac signal, and gene
expression values (normalized reads per kilobase million) of the nearest gene(s) in male (x-axis) and female (y-axis) GBM astrocytes for male-biased (A),
female-biased (B), and shared (C) genes are plotted. The percentage of genes enriched in each sex is indicated at the top left (female) and bottom right (male)
of each graph. Log2 fold changes (Log2FC) of the gene expression value following JQ1 treatment are indicated in the far-right column and are plotted as
above. Most genes are located in the bottom left quadrant, indicating down-regulation of the gene in both sexes following JQ1.
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present in the human GBM cell lines. This result was also supported by the sex difference in proliferation following BETi
identified in the CTRP datasets. Thus, the sex-specific effects of
Brd4 inhibition on tumorigenic phenotype and response to treatment observed in our murine GBM model extend to human GBM
cells. Collectively, the concordance of data generated from three
different GBM models provide strong evidence for the generalizability of our results generated from the murine GBM model.
Taken together, these results demonstrate that sex differences in
GBM cellular phenotypes are mediated by differential Brd4bound enhancers and that reduced Brd4 function results in differing sex-dependent effects in both mouse models and human
patients. These data further affirm the sex-dependent role of Brd4
in regulating tumorigenesis in GBM and demonstrate how clinically important it will be to consider sex in the design of clinical
trials and the decision making for treatment of cancer patients.
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Brd4-Bound Enhancers Regulate Sex Differences in GBM. Having
established that Brd4-bound enhancers mediate sex difference in
our murine model of GBM, we next sought to determine the
transcriptional pathways responsible for these basal sex differences.
To do so, we used our Brd4-binding data in male and female GBM
astrocytes to categorize Brd4-regulated genes as male biased
(Fig. 4A), female biased (Fig. 4B), or shared (Fig. 4C). Although
these genes were categorized using only Brd4-binding data, we
found a high degree of concordance with H3K27ac intensity and
gene expression within each category. When considered as a group,
95% of the male-biased Brd4-regulated genes displayed more
H3K27ac signal in males, and 72% were more highly expressed in
males (Fig. 4 A, P value < 10−6), while 93% of the female-biased
Brd4-regulated genes displayed more H3K27ac signal in females, and
67% were more highly expressed in females (Fig. 4 B, P value < 10−6).

These results demonstrate that sex-biased Brd4 binding correlated
with sex-specific gene expression patterns.
To determine which sex-biased genes were modulated after
treatment with a BET inhibitor, we performed RNA-seq on male
and female GBM cells treated with JQ1, one of the BET inhibitors that had a strong sex-biased effect on clonogenicity (SI
Appendix, Fig. S1D). Briefly, cells were treated with either vehicle (0.05% DMSO or 500 nM JQ1) for 24 h prior to RNA
isolation. Gene expression analysis of JQ1- and DMSO-treated
cells revealed that JQ1 treatment predominantly down-regulated
gene expression (Fig. 4, last column of scatterplots, and SI Appendix, Fig. S4A). In addition, genes proximal to Brd4-binding sites
were significantly down-regulated compared to genes that were
distal to Brd4-binding sites (P < 0.01), indicating that JQ1 had a
specific and directed effect on genes whose expression was driven
by Brd4-bound enhancers (SI Appendix, Fig. S4B). Pathway analysis of sex-biased Brd4-bound enhancer associated genes downregulated following JQ1 treatment in male and female GBM
cells revealed functionally important pathways, such as chromosome aberrations, integrin signaling, and stem cell proliferation in
males and immune system process, cell cycle, and transforming
growth factor-beta signaling in females (SI Appendix, Table S4).
To begin to understand the sex-specific stem cell response to
BETi, we focused our attention on the functions of the sexbiased male and female Brd4-bound enhancer genes under
basal conditions. Functional classification of these genes using
pathway enrichment analysis revealed that male GBM cells were
highly enriched for cancer, neoplastic, and pluripotent stem cell
pathways, while female GBM cells were mainly enriched for
neural stem cell and stem cell proliferation pathways (SI Appendix, Fig. S5A). Representative examples of these pathways are
depicted in SI Appendix, Fig. S5 B and C. Male-biased genes in
stem cell pathways included well-known oncogenes, such as Myc,

Fig. 5. BET inhibitors have sex-specific effects on in vivo tumorigenicity in male and female GBM astrocytes. (A) Representative flank tumors from DMSO- or
JQ1-treated male GBM astrocyte-initiated tumors. (B) Representative flank tumors from DMSO- or CPI0610-treated female GBM astrocyte-initiated tumors.
(C) Fraction of male and female GBM cell implants that formed tumors following treatment with DMSO, JQ1 (500 nM), or CPI0610 (1 μM). JQ1-treated male
GBM cells were significantly less likely to form tumors than DMSO-treated male GBM cells (Fisher’s exact test P < 0.0003), while CPI0610-treated female GBM
cells were significantly more likely to form tumors than DMSO-treated female GBM cells (Fisher’s exact test P < 0.0092). The bar graph represents the percent
tumor formation under each treatment condition. Notably, JQ1-treated male GBM cells show a decrease in their tumor formation capacity equivalent to the
control DMSO-treated female GBM cells, whereas CPI0610-treated female GBM cells had an increase in tumor formation capacity almost equivalent to control
DMSO-treated male GBM cells.
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Motif Analysis at Sex-Biased Brd4-Bound Enhancers Identifies Candidate
Transcription Factor Drivers of Sex Differences in the Tumorigenic
Phenotype. Our results suggest that male and female GBM cells

reside in two distinct transcriptional states established by the actions
of Brd4. Inhibiting Brd4 function abrogates the sex differences in
these transcriptional states and the concomitant differences in tumorigenic phenotype. As Brd4 does not bind DNA directly, but
instead is recruited to enhancers by transcription factors either directly or indirectly though histone acetylation, we sought to identify
candidate transcription factors (TFs) responsible for the recruitment of Brd4 to sex-biased genomic loci. To do so, we searched for
TF-binding motifs enriched at male-biased or female-biased Brd4bound enhancers. TFs enriched at male-biased Brd4-bound enhancers included oncogenes and stem cell markers, such as Myc,
Klf5, and Oct4, whereas female-biased Brd4-bound enhancers were
co-occupied and enriched with TFs with tumor suppressor functions, such as p53 and Smad4 (Table 1). These results could explain
the observed dual functions of Brd4 in male and female GBM cells.
Future studies, including knock-in and knockout of transcriptional
master regulators and partners of Brd4, are warranted to investigate
the dual functions of Brd4 as an oncogene in male GBM cells and a
tumor suppressor in female GBM cells.
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BET Inhibitors Have Sex-Specific Effects on In Vivo Tumorigenicity in
Male and Female Mouse GBM Astrocytes. The results described thus

far suggested to us that Brd4-bound enhancers play an important
role in maintaining sex differences in our murine GBM model.
However, these experiments all measured in vitro surrogates for
the tumorigenic phenotype. Therefore, we next sought to determine what role, if any, Brd4 plays during in vivo tumorigenesis.
We treated male and female murine GBM astrocytes with BETi
and used these cells to perform in vivo tumor flank implantation
studies in female nude mice. Only females were used as recipients
for tumor flank implantation because we have previously shown
that the sex of the recipient mouse does not affect the in vivo
growth of implants in this murine model (19). Based on our
in vitro ELDA studies, we chose to use JQ1 and CPI0610, the two
BETi with the most dramatic sex-specific effect in male and female GBM astrocytes, respectively. Each mouse underwent flank
Kfoury et al.
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implantation of DMSO-, JQ1-, or CPI0610-treated male cells
(5,000 cells) or DMSO-, JQ1- or CPI0610-treated female cells (1.5
million cells). The sex differences in cell dose were empirically
determined to match the timeframe for in vivo tumor growth up to
the threshold for euthanasia. We attribute the sex differences in
tumor growth kinetics to differences in clonogenic cell frequency
and rates of proliferation (18, 19). Tumor formation was monitored by observers blinded to group assignment for 7 to 16 wk.
Flank implantation of JQ1-treated male GBM cells was less likely
to result in tumor formation than implantation with control
DMSO-treated male cells (Fig. 5 A and C). In contrast, flank
implantation of CPI0610-treated female GBM cells was more
likely to result in tumor formation than implantation with control
DMSO-treated female cells (Fig. 5 B and C). These results are
consistent with the sex-specific effects of JQ1 and CPI0610 on
in vitro clonogenic cell frequency and cell growth. This effect was
seen following only one dose of BETi prior to implantation, suggesting that this robust response is maintained and manifested at
the epigenetic level. Both JQ1 and CPI0610 display a similar
pattern in their selectivity to target the different Brd family
members, with the highest selectivity for Brd4 (Fig. 3D). Although
both drugs had a similar sex-specific directional effect on clonogenic frequency in male and female cells, the magnitude of their
effect differed in both the clonogenic cell frequency and in vivo
tumorigenic assays. A possible explanation for this discrepancy is
that the BETi treatment could be affecting different or multiple
Brd family members. To rule out this possibility and validate that
the sex-biased response to treatment was driven by Brd4, we
treated male and female control and Brd4 knockdown cells with
either 0.05% DMSO, 500 nM JQ1, or 1 μM CPI0610 and then
performed ELDA to compare clonogenic cell frequency. No significant difference in the effect on clonogenic cell frequency was
observed between control and Brd4 knockdown cells treated with
BETi, indicating that Brd4 is required for sex-specific responses to
BETi (SI Appendix, Fig. 6). Although it is still unclear why we
observe different magnitude effects of these two BETi, the fact
that both drugs show a sex-specific effect in vivo is notable and
predicted by our earlier observations. These results provide strong
and critical evidence that the biology of sex affects cancer incidence and outcome and addressing these sex differences in cancer
will be fundamental to improving outcomes and a better quality of
life for cancer patients.
Discussion
Sex differences in the incidence and severity of numerous human
diseases, including cancer, are substantial and demand an understanding at a molecular level. Despite the abundant data in
the literature supporting an important role for sex on incidence,
prognosis, and mortality in cancer, there has been limited effort,
until recently, to include sex as a biological variable in the design
of clinical trials, data analysis, and treatment (3, 12, 20, 60–63).
New approaches to treatment could be revealed by dissecting the
biological and molecular mechanisms that drive sex differences
in phenotype. Similar to other cancers, GBM has a higher incidence in males compared to females with a ratio of 1.6:1 (63).
Additionally, after developing GBM, males tend to have a
shorter median survival of 17.5 mo compared to 20.4 mo for
females (64). Recently, we found that longer survival for male
and female GBM patients after standard surgery, radiation, and
chemotherapy is associated with different transcriptional programs
(20). Using a JIVE (joint and individual variation explained) algorithm, male and female patients with GBM cluster into five distinct
male and female subtypes distinguished by gene expression and
survival. Although, a recent study by Yuan et al. (65) assigned GBM
as a weak sex-effect cancer, their analysis of the TCGA GBM human patient data was performed using a propensity score algorithm,
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Tet1, and Lif, while female-biased genes included tumor suppressors, such as Six2 and Six3. Based on these results and our
previous observation of a sex-dependent differing response in
clonogenicity following Brd4 inhibition with JQ1, we examined
the effects of JQ1 treatment on the expression of stem cell
pathway genes. As BETi reduced sex differences in clonogenicity, we hypothesized that sex differences in the expression of
stem cell–related genes present in male and female GBM cells
under basal conditions would be eliminated by JQ1 treatment,
accounting for the abrogation of sex differences in the tumorigenic phenotype. We identified genes with sex differences in
expression at baseline that became equivalent following JQ1
treatment and performed pathway analysis. As anticipated, the
cancer stem cell pathway was affected by JQ1 treatment (SI
Appendix, Fig. S5D). Concordant with differential growth responses, JQ1 down-regulated male-biased genes, while JQ1 upregulated female-biased genes. The fold change in expression
following JQ1 treatment (ratio of JQ1/DMSO) is depicted above
or below each gene. Overall, there was concordance with the
direction of change in gene expression and the decrease and
increase in stem cell function in male and female ELDA assays,
respectively. These results support the existence of Brd4regulated sex-specific transcriptional programs that mediate
key functional properties of GBM, including clonogenicity.
Identifying the specific pathways critical to sex differences in
GBM will require further functional studies.
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a more standard approach compared to the specialized JIVE
analysis we have previously adapted in our analysis of the TCGA
GBM transcriptome datasets (20).
The epigenetic mechanisms involved in GBM initiation and
treatment response have been heavily investigated in the past few
years and include epigenetic readers, writers, erasers, and histone
proteins (25, 26, 66–68). The strong evidence for epigenetic dysregulation in GBM has led to clinical trials of multiple drugs
targeting tumor epigenetics in hope of improving treatment response in patients (24, 27, 29, 69). However, sex differences in the
epigenetic landscape in male and female cells have not been taken
into account when investigating cancer risk or treatment response.
As sexual differentiation is in large part an epigenetic phenomenon and sex differences are found in the epigenetic landscape of
male and female cells, it will be critical to examine the efficacy of
therapies in both sexes separately to avoid missing important
clinical effects when data are compiled from both sexes. Studying
disparities in threshold for transformation in male and female cells
will provide a powerful tool to investigate epigenetic mechanisms
that establish a dimorphic tumorigenic phenotype and better
treatment and survival outcomes for cancer patients.
Our study establishes that sex-biased Brd4 activity drives sex
differences in the GBM tumorigenic phenotype and renders male
and female tumor cells differentially sensitive to BETi. Using our
murine GBM model, in which male and female cells are syngeneic
except in their sex chromosomes, we discovered transcriptome-wide
sex differences in gene expression, H3K27ac marks, and Brd4bound enhancers in male and female GBM cells. Brd4 is an epigenetic reader that promotes stem-like conversion and pluripotency
(26, 28, 36), and its inhibition has shown therapeutic activity in a
number of different cancer models (37–41). Sex-biased Brd4-bound
enhancers, identified in our study, were also enriched for H3K27ac,
indicative of sex-biased highly active enhancer regions. These sexspecific gene expression patterns were evident in human GSCs.
validating our model to recapitulate the human GBM phenotype.
Thus, sex is established as an intrinsic element of cellular identity
that is driven by Brd4 activity in GBM.
To validate whether the phenotypic differences in male and
female GBM cells were indeed mediated by Brd4, as suggested by our
transcriptome-wide gene expression and Brd4 binding analyses, we
performed Brd4 knockdown using shRNA in male and female GBM
cells. Brd4 depletion decreased clonogenic stem cell frequency in male
cells while increasing it in female cells, abrogating the sex differences
observed in the tumorigenic phenotype. These results suggest that
differential sex-biased Brd4 localization may be responsible for the
sex differences in GBM. These data emphasize the importance of
understanding and including the fundamentals of the biology of
sex while investigating epigenetic mechanisms of tumorigenesis.
As bromodomain inhibitors are currently being evaluated in
clinical trials, we hypothesized that this differential sex-biased
Brd4 localization in male and female GBM cells would contribute to a differential response to BETi. Male and female
murine and human GBM cells responded in differing ways to
BETi. Consistent with our knockdown data, this dimorphism in
Brd4 function was linked to the sex of the experimental cells and
correlated with sex-specific patterns of Brd4 localization
throughout the genome, which renders male and female cells
differentially sensitive to BETi. Accordingly, BETi decreased the
growth of male in vivo tumors but increased growth of female
tumors. These results strongly indicate that sex differences in
disease biology translate into sex differences in therapeutic responses. The sex-specific response to the inhibition of Brd4 in our
GBM model could help explain previously published data in
breast and prostate cancer, wherein ectopic expression of Brd4
in breast cancer cells decreased invasiveness and tumor growth,
while Brd4 inhibition decreased viability of prostate cancer cells
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(40, 70–72). These studies also revealed that in women with estrogen
receptor positive breast cancer (70) or endometrial cancer (71),
low Brd4 expression correlated with worse survival. This is in
contrast to men with prostate cancer, in whom low levels of Brd4
are associated with improved survival (40, 71). The sex-specific
response of primary human GBM cells to BETi corroborated
data obtained from the CTRP that show human male GBM cells
to be more sensitive to BETi, displaying slower growth and increased cell death compared to human female GBM cells.
The functions of Brd4 are determined by the action of master
transcriptional regulators that bind directly or indirectly to Brd4
and dictate its localization in the genome. We performed a
motif-based analysis to identify potential TFs that endow Brd4
with its pro- or anti-tumorigenic functions. This analysis revealed
that Brd4 colocalized in a sex-biased manner with Myc and p53
in male and female GBM cells, respectively. These results are
consistent with previously published data investigating sex differences in gene expression and regulatory networks in multiple
human tissues. The study revealed that multiple TFs, although
not differentially expressed between male and female cells, display sex-biased regulatory targeting patterns (2). These results
warrant further functional studies to validate whether these
master TFs drive the sex differences in Brd4-bound enhancer
activity (sex-biased Brd4 genomic localization) and, therefore, the
sex differences in tumorigenic phenotype and response to BETi.
Given that Brd4 is shown to have pleiotropic functions in the
regulation of gene expression, these results suggest that Brd4 can
exhibit dual functions in GBM as an oncogene or a tumor suppressor, dependent upon cellular sex. Further functional and
mechanistic experiments are warranted to ascertain this Brd4 dual
function in GBM. We previously presented evidence for cellintrinsic sex differences rendering male and female cells differentially vulnerable to malignant transformation. We showed that
murine male and female GBM cells displayed differences in cell
cycle regulation through differential RB inactivation (19). These
data, in addition to our newly identified role for Brd4 in regulation
epigenetic mechanisms involved in stem cell function, could further explain the sex differences in the male and female GBM cells
tumorigenic phenotypes.
The consistency between our mouse and human data (GBM
cell lines, GSCs, and CTRP) and published breast and prostate
cancer studies provides strong evidence for context-dependent, sexspecific dual roles of Brd4 in regulating gene expression programs in
oncogenesis. In future work, we will take advantage of this remarkable sex difference in Brd4 function in GBM to better define
the molecular basis for Brd4 pleiotropy in cancer and mechanisms
of resistance to Brd4 inhibitors. As BETi are currently being
evaluated in a number of clinical trials, understanding this phenomenon is of critical importance, both for the interpretation of
existing trials and to guide better application of these drugs. Increasing our knowledge of these sex-biased genetic and epigenetic
mechanisms will lead to a greater understanding of cancer biology
and its relationship to normal development. We have identified
sex-biased Brd4-regulated genes and pathways, which could
translate into new and promising therapeutic targets to enhance
survival for all GBM patients and potentially other cancers that
exhibit substantial sex differences in incidence or outcome.
Materials and Methods
Please find in SI Appendix, Supplementary Materials and Methods detailed
descriptions of mouse male and female GBM cells; ChIP-seq for H3K27ac;
RNA sequencing; pathway analysis; GSCs gene expression data analysis; realtime qPCR; shRNA lentiviral infection and knockdown of Brd2, Brd3, and
Brd4; ELDA analysis, growth assays, and CTRP data analysis, in vivo tumorigenesis: flank implantation, bioinformatic motif analysis, and statistical
analysis.
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Although male and female GBM cells have a different number of X
chromosomes, one X chromosome is inactivated in female cells, and so the
amount of accessible chromatin has been found to be similar in both cell types
(75). For this reason, we treated the X chromosome in an identical manner to
the autosomes for peak calling. However, to explore how sensitive our
analysis was to this assumption, we recalculated P values for peaks on the X
chromosome as we adjusted the insertions in male cells with a multiplier
from 1 to 2 (using a step size of 0.1). The total number of male-biased peaks
varied from 2,679 to 2,995 and the total number of female-biased peaks
varied from 2,778 to 2,727, indicating that the vast majority of differential
bound peaks in our analysis are robust to the actual percentage of accessible
chromatin on the inactivated X chromosome.
ChIP-seq datasets for H3K27ac were aligned to the murine genome build
mm10 using Bowtie 2 (version 2.3.4.3), and only uniquely aligning reads
were used for downstream analyses (73). Regions of enrichment of H3K27ac
over the background were calculated using the MACS version (2.1.0) peak
finding algorithm (74). An adjusted P value threshold of enrichment of 0.01
was used for all datasets. The resulting peak files were used as inputs for
DiffBind (version 3.5) to derive consensus peak sets (76, 77). The differential
enrichment of H3K27ac signals between male and female analysis was carried out with DiffBind using DESeq2 (method = DBA_DESEQ2) with libraries
normalized to total library size.
RNA-seq datasets were aligned to the transcriptome and the whole genome with Spliced Transcripts Alignment to a Reference (STAR) (version
2.7.0) (78). Genes or exons were filtered for just those that were expressed.
The read-count tables for annotated genes in the mm10 gene transfer format (.GTF) file were derived from uniquely aligned reads using HTSeq
(version 0.11.1) (79). The raw counts for each gene were converted into
transcripts per million (TPM) that is more appropriate for comparisons of
gene expression levels between samples (80–82). TPMs from biological replicates were averaged for subsequent analysis. Differential gene expression
between pairs of samples was computed using DESeq2 (version 1.28.1) and
was filtered by FDR < 0.05 for differentially expressed genes (83). In in some
cases, a twofold change was also applied as a filter for identifying differentially expressed genes between two conditions.

Sequencing Data Alignment and Analysis. Raw reads from transposon calling
cards were aligned to the murine genome build mm10 using Bowtie 2 (version
2.3.4.3) (73). Significant calling card peaks or Brd4-enriched enhancer sites
were identified by a modified version of the previously described algorithm,
which also has similarities to the MACS2 ChIP-seq peak caller (43). Briefly,
transposon insertions were grouped into peaks using a hierarchical clustering
algorithm with a maximum distance of 5 kb between insertions. Significant
peaks were identified using Poisson distribution to test for enrichment over the
background (unfused transposase) calling card data with an adjusted P value
threshold less than 0.05. The expected number of transposon insertions per
TTAA was estimated by considering the total number of insertions observed in
a large region of 100 kb distance centered at the calling card cluster/insertion.
We computed a P value based on the expected number of insertions and
identified Brd4-enriched enhancer sites using Poisson distribution.
To identify the sites with an excess of Brd4 insertions in male GBM cells
relative to female cells, we used the algorithm from ChIP-seq peaks caller
MACS (version 2.1.0) (74) but modified for the analysis of calling card data.
First, the Brd4-enriched enhancer sites from both male and female cells were
merged if they overlapped by 1 bp. For each merged or unmerged enhancer
site, the normalized insertions from the female samples were used to compute
the lambda of Poisson distribution. We then computed a P value from the cumulative distribution function of the observed number of independent insertions
in the male sample. Brd4-binding sites with a P value less than 0.05 and with
more than 20 insertions were considered as Brd4-binding sites significantly
enriched in male samples. To identify the Brd4 sites with an excess of insertions in
female GBM cells relative to male cells, we performed the same analysis,
substituting the male and female datasets.
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